Acrux signs second distribution agreement with CSL

By Melissa Trudinger
Tuesday, 30 November, 2004

Acrux (ASX: ACR) has signed a second distribution agreement with CSL (ASX: CSL), giving CSL the rights to distribute Acrux's Fentanyl MDTS treatment for severe pain.

The product, which is undergoing Phase I clinical development, will be distributed by CSL Pharmaceuticals in Australia and New Zealand. Acrux will receive both an upfront payment plus royalties on net sales.

Earlier this year, CSL agreed to distribute Acrux's testosterone MDTS treatment for low testosterone levels and sexual dysfunction in women.

Content from other channels on our network

$10m project to safeguard WA water supplies

Supermarket giant now powered using 100% renewables

CAWSYD26 to spotlight local climate solutions

Chip makes pH measurements easier

Adsorbents capture short-chain PFAS in water

Australian researchers create graphene from peanut waste

Banksia Minerals gets $5m for critical energy mineral processing

Cloud-based SCADA to integrate renewable energy sites

CSIRO opens $3m upgrade to renewable energy lab

UNSW researchers find way to turn high‍-‍emissions waste into fertiliser

Clariant achieves EU approval for renewable additives in food-contact plastics

Opal Packaging Plus partners with Phantm to develop packaging compliance solution

Public consultation about restricting infant formula marketing in Australia

French fries maker installs fully integrated processing line

Mondi spices up high-barrier paper packaging for food maker

Acrux signs second distribution agreement with CSL

AusBiotech and Proto Axiom partner on investor-focused life sciences programs

The University of Sydney formalises cervical cancer elimination partnership

Noxopharm says paper reveals science behind its immune system platform

Content from other channels on our network